VCAP Therapy for Multiple Myeloma

DOI Web Site PubMed 2 Citations
  • UMEDA Masanori
    First Department of Internal Medicine, Toho University, School of Medicine
  • KANEKO Haruo
    First Department of Internal Medicine, Toho University, School of Medicine
  • KATOH Masako
    First Department of Internal Medicine, Toho University, School of Medicine
  • YAMAGUCHI Ryozo
    First Department of Internal Medicine, Toho University, School of Medicine
  • MASAKI Tamio
    First Department of Internal Medicine, Toho University, School of Medicine
  • ISHIKAWA Itaru
    First Department of Internal Medicine, Toho University, School of Medicine
  • YAMAUCHI Mikio
    First Department of Internal Medicine, Toho University, School of Medicine
  • KIGA Yutaka
    First Department of Internal Medicine, Toho University, School of Medicine
  • HARA Akihiro
    First Department of Internal Medicine, Toho University, School of Medicine
  • NOJIMA Zensei
    First Department of Internal Medicine, Toho University, School of Medicine
  • TSUKAHARA Toshihiro
    First Department of Internal Medicine, Toho University, School of Medicine
  • SHIRAI Tatsuo
    First Department of Internal Medicine, Toho University, School of Medicine

Bibliographic Information

Other Title
  • 多発性骨髄腫に対するVCAP療法
  • タハツセイ コツズイシュ ニ タイスル VCAP リョウホウ

Search this article

Abstract

Twenty-six patients with multiple myeloma, who had not recieved any previous chemotherapy, were treated with a VCAP regimen consisting of vincristine, cyclophosphamide, Adriamycin and prednisolone. This regimen was used not only for remission induction chemotherapy, but for maintenance therapy as well.<br>The response rate, evaluated by 50% or more reduction of M-protein, was 69% (18 of 26 patients). The median survival time was 44 months, which was longer than that reported by Alexanian. The patients in stage II survived longer than those in stage III, but the difference was not significant (p>0.05). The median survival times of the patients in stage IIIB and IIIA were 8.5 months and more than 49 months, respectively. Side effects, including leukopenia, gastrointestinal discomforts, peripheral neuropathy, and alopecia, were not serious.<br>These results suggest that the VCAP regimen is a useful combination chemotherapy for patients with multiple myeloma and that a maintenance therapy employing this regimen may prolong patients' survival time.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 28 (7), 1147-1151, 1987

    The Japanese Society of Hematology

Citations (2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top